Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
Earnings Data
Report Date
Nov 05, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.08Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted several significant achievements, particularly the approval of ivonescimab in China and successful clinical trial results, indicating a promising outlook for Summit Therapeutics. Despite some concerns over increased operating expenses and uncertainty in OS benefit, the sentiment remains largely optimistic.Company Guidance
Ivonescimab Approval in China
Ivonescimab received approval from NMPA, the health authority in China, as frontline monotherapy treatment for patients with NSCLC whose tumors have positive PD-L1 expression. This approval is based on positive PFS results from Akeso's HARMONi-2 trial.
Positive Interim Analysis Results
An early interim analysis requested by the NMPA showed a clinically meaningful and strongly positive trend favoring ivonescimab with a hazard ratio of 0.777, implying a potential 22% reduction in the risk of death compared to pembrolizumab.
HARMONi-6 Phase III Trial Success
HARMONi-6 Phase III trial met its primary endpoint of progression-free survival, showing statistically significant and clinically meaningful improvement in PFS for ivonescimab plus chemotherapy against tislelizumab plus chemotherapy in advanced squamous NSCLC.
Expansion of Clinical Trials
Summit has initiated multiple global Phase III studies, including HARMONi-3 and HARMONi-7, evaluating ivonescimab in different settings of NSCLC. Additionally, collaborations with institutions like MD Anderson and Pfizer are expanding research into other cancer types.
Strong Financial Position
Summit ended Q1 2025 with a cash position of approximately $361 million and remains debt-free.
SMMT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SMMT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 11, 2025 | $28.25 | $25.68 | -9.10% |
May 01, 2025 | $24.67 | $27.90 | +13.09% |
Feb 24, 2025 | $22.12 | $18.84 | -14.83% |
Oct 30, 2024 | $21.83 | $18.65 | -14.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Summit Therapeutics (SMMT) report earnings?
Summit Therapeutics (SMMT) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
What is Summit Therapeutics (SMMT) earnings time?
Summit Therapeutics (SMMT) earnings time is at Nov 05, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SMMT EPS forecast?
SMMT EPS forecast for the fiscal quarter 2025 (Q3) is -0.17.